Mitochondrial uncoupling therapeutic - Protheragen
Latest Information Update: 28 Jul 2024
At a glance
- Originator Protheragen
- Class Hepatoprotectants
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 22 Jun 2020 Mitochondrial uncoupling therapeutic is available for licensing as of 22 Jun 2020. https://www.protheragen.com/pipeline.html
- 22 Jun 2020 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route), prior to June 2020 (Protheragen pipeline, June 2020)